Investigating miRNA subfamilies: Can they assist in the early diagnosis of acute myocardial infarction?

Drug Discov Today. 2023 Oct;28(10):103695. doi: 10.1016/j.drudis.2023.103695. Epub 2023 Jul 3.

Abstract

This report focuses on small non-coding RNA molecules (miRNAs), which have emerged as potential biomarkers with variable diagnostic values and false-positives in different conditions that limit their clinical preference. Current investigations focus on small non-coding RNA molecules (miRNAs), which have emerged as potential biomarkers with variable diagnostic values and false-positives in different conditions that limit their clinical preference. We thoroughly scrutinize the leading pathology of myocardial infarction and contemporary alterations in miRNAs for their specificity, stability and significant prognostic value at the early stage of acute myocardial infarction (AMI). Based on secondary data analysis, we explore common biomarkers and further investigate included miRNA biomarkers for their specificity, stability and area under the curve (AUC) values. We conclude that a group of novel biomarkers, including miRNA-1, miRNA-208a/b and miRNA-499, could help predict the emergence of AMI at an early stage.

Keywords: cardiac biomarkers; early diagnostic; miRNAs; molecular signaling; myocardial infarction; prognosis.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Biomarkers
  • Early Diagnosis
  • Humans
  • MicroRNAs* / genetics
  • Myocardial Infarction* / diagnosis
  • Myocardial Infarction* / genetics
  • Prognosis

Substances

  • MicroRNAs
  • Biomarkers
  • MIRN499 microRNA, human